1. Home
  2. SHEN vs PHAT Comparison

SHEN vs PHAT Comparison

Compare SHEN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHEN
  • PHAT
  • Stock Information
  • Founded
  • SHEN 1902
  • PHAT 2018
  • Country
  • SHEN United States
  • PHAT United States
  • Employees
  • SHEN N/A
  • PHAT N/A
  • Industry
  • SHEN Telecommunications Equipment
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHEN Telecommunications
  • PHAT Health Care
  • Exchange
  • SHEN Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • SHEN 726.3M
  • PHAT 835.7M
  • IPO Year
  • SHEN N/A
  • PHAT 2019
  • Fundamental
  • Price
  • SHEN $13.36
  • PHAT $10.75
  • Analyst Decision
  • SHEN Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • SHEN 1
  • PHAT 5
  • Target Price
  • SHEN $26.00
  • PHAT $16.40
  • AVG Volume (30 Days)
  • SHEN 300.2K
  • PHAT 1.2M
  • Earning Date
  • SHEN 11-06-2025
  • PHAT 11-06-2025
  • Dividend Yield
  • SHEN 0.76%
  • PHAT N/A
  • EPS Growth
  • SHEN N/A
  • PHAT N/A
  • EPS
  • SHEN N/A
  • PHAT N/A
  • Revenue
  • SHEN $349,477,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • SHEN $11.97
  • PHAT $213.11
  • Revenue Next Year
  • SHEN $9.07
  • PHAT $91.84
  • P/E Ratio
  • SHEN N/A
  • PHAT N/A
  • Revenue Growth
  • SHEN 20.36
  • PHAT 1049.82
  • 52 Week Low
  • SHEN $9.77
  • PHAT $2.21
  • 52 Week High
  • SHEN $16.28
  • PHAT $19.50
  • Technical
  • Relative Strength Index (RSI)
  • SHEN 47.70
  • PHAT 42.71
  • Support Level
  • SHEN $13.02
  • PHAT $11.74
  • Resistance Level
  • SHEN $13.90
  • PHAT $12.97
  • Average True Range (ATR)
  • SHEN 0.40
  • PHAT 0.85
  • MACD
  • SHEN -0.02
  • PHAT -0.10
  • Stochastic Oscillator
  • SHEN 21.71
  • PHAT 17.92

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: